ICD trials: An extraordinary means of determining patient risk?

Seah Nisam, Morton Mower

Research output: Contribution to journalEditorialpeer-review


Extensive clinical experience with the implantable cardioverter defibrillator (ICD) combined with recently completed prospective, randomized trials like MADIT and AVID, have demonstrated the lifesaving efficacy of this therapy and its superiority compared to conventional medical management in treating patients at high risk of sudden arrhythmic death. This evidence has in turn spurred great interest in further ICD studies. Since the ability of the ICD to save lives is no longer in question, there is a need to reexamine the real objectives of these new studies.

Original languageEnglish (US)
Pages (from-to)1341-1346
Number of pages6
JournalPACE - Pacing and Clinical Electrophysiology
Issue number7
StatePublished - Jul 23 1998


  • Implantable defibrillator
  • Prospective studies
  • Risk stratification

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'ICD trials: An extraordinary means of determining patient risk?'. Together they form a unique fingerprint.

Cite this